NCT00038558已完成3 期
Prophylactic Use of Filgrastim SD/01 In Patients With Hodgkin's Disease Receiving ABVD Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Number of Patients with Response to Prophylactic Filgrastim SD/01Chemotherapy
研究概览
简要总结
Prophylactic use of Filgrastim SD/01 for patients with Hodgkin's lymphoma receiving ABVD chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Filgrastim + ABVD Chemotherapy
Experimental
干预措施: Filgrastim SD/01 (Drug)
Filgrastim + ABVD Chemotherapy
Experimental
干预措施: Adriamycin (Drug)
Filgrastim + ABVD Chemotherapy
Experimental
干预措施: Bleomycin (Drug)
Filgrastim + ABVD Chemotherapy
Experimental
干预措施: Vinblastine (Drug)
Filgrastim + ABVD Chemotherapy
Experimental
干预措施: DTIC (Drug)
结局指标
主要结局
Number of Patients with Response to Prophylactic Filgrastim SD/01Chemotherapy
时间窗: Following ABVD chemotherapy course
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's DiseaseHodgkin's DiseaseHIV InfectionsNCT00000626National Institute of Allergy and Infectious Diseases (NIAID)27
已完成
2 期
Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)Unresectable Locally Advanced NSCLCNCT00682383Mt. Sinai Medical Center, Miami26
已完成
2 期
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By SurgeryEstrogen Receptor-negative Breast CancerEstrogen Receptor-positive Breast CancerHER2-positive Breast CancerProgesterone Receptor-negative Breast CancerProgesterone Receptor-positive Breast CancerStage IA Breast CancerStage IB Breast CancerStage II Breast CancerStage IIIA Breast CancerNCT00194779University of Washington50
进行中（未招募）
1 期
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)Hodgkin LymphomaNCT03033914Memorial Sloan Kettering Cancer Center82
已完成
1 期
A Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial InfarctionAcute Myocardial InfarctionNCT00215124The Cleveland Clinic